

Adintrevimab

Cat. No.:	HY-P99423
CAS No.:	2516243-54-0
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential ^[1] .														
In Vitro	<p>The crystallizable fragment (Fc) region of Adintrevimab has a modification to extend its half-life. Adintrevimab binds to a distinct epitope in the receptor-binding domain of the spike glycoprotein of SARS-CoV-2 that partially overlaps the angiotensin-converting enzyme 2 binding site and is highly conserved among sarbecoviruses. In vitro, Adintrevimab has demonstrated potent neutralizing activity against most variants and sublineages of SARS-CoV-2 (including Alpha, Beta, Gamma, and Delta) as well as other SARS-like viruses. Adintrevimab displays reduced in vitro activity against Omicron BA.1/BA.1.1 and lacks activity against BA.2, BA.3, BA.4, and BA.5^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>														
In Vivo	<p>Adintrevimab (9.25, 55, 333, or 2,000 µg; i.p.; once) provides protection against SARS-CoV-2/WA1/2020 infection in a dose-dependent manner^[1].</p> <p>Adintrevimab (5-25 mg/kg; i.v.; once) provides protection against SARS-CoV-2/WA1/2020 infection in a dose-dependent manner^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Syrian golden hamsters (5-6-week-old females; 75-125 g) infected with SARS-CoV-2/WA1/2020^[1].</td> </tr> <tr> <td>Dosage:</td> <td>9.25, 55, 333, or 2,000 µg (average range: 0.1 to 20 mg/kg)</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; single dose</td> </tr> <tr> <td>Result:</td> <td>Showed significant reduction in lung viral load and virus-induced lung pathology.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Rhesus macaques (5.6-8.8 years old; 6 females [4.4-6.3 kg] and 6 males [6.1-8.5 kg]) infected with SARS-CoV-2/WA1/2020^[1].</td> </tr> <tr> <td>Dosage:</td> <td>5 mg/kg, 25 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; single dose</td> </tr> </table>	Animal Model:	Syrian golden hamsters (5-6-week-old females; 75-125 g) infected with SARS-CoV-2/WA1/2020 ^[1] .	Dosage:	9.25, 55, 333, or 2,000 µg (average range: 0.1 to 20 mg/kg)	Administration:	Intraperitoneal injection; single dose	Result:	Showed significant reduction in lung viral load and virus-induced lung pathology.	Animal Model:	Rhesus macaques (5.6-8.8 years old; 6 females [4.4-6.3 kg] and 6 males [6.1-8.5 kg]) infected with SARS-CoV-2/WA1/2020 ^[1] .	Dosage:	5 mg/kg, 25 mg/kg	Administration:	Intravenous injection; single dose
Animal Model:	Syrian golden hamsters (5-6-week-old females; 75-125 g) infected with SARS-CoV-2/WA1/2020 ^[1] .														
Dosage:	9.25, 55, 333, or 2,000 µg (average range: 0.1 to 20 mg/kg)														
Administration:	Intraperitoneal injection; single dose														
Result:	Showed significant reduction in lung viral load and virus-induced lung pathology.														
Animal Model:	Rhesus macaques (5.6-8.8 years old; 6 females [4.4-6.3 kg] and 6 males [6.1-8.5 kg]) infected with SARS-CoV-2/WA1/2020 ^[1] .														
Dosage:	5 mg/kg, 25 mg/kg														
Administration:	Intravenous injection; single dose														

Result:	Reduced pulmonary inflammation.
---------	---------------------------------

CUSTOMER VALIDATION

- JCI Insight. 2023 Sep 7;e166540.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Elizabeth E Zumbrun, et al. Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19. Antimicrob Agents Chemother. 2022 Dec 15;e0135322.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA